Glynn Wilson reports a stock award at Cadrenal Therapeutics

By AlphaYouPublished Oct 13, 2026Form 4

Stocks in this disclosure

Reported activity

WILSON GLYNN

Reporting filer

Glynn Wilson reports a stock award, not an open-market purchase or sale, in Cadrenal Therapeutics, Inc.. Form 4 filed Oct 13, 2026 lists 1 entry.

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Stock Option (derivative)	WILSON GLYNN	2026-10-09	A	Grant or award	75000	0	75,000	4 days	Filed terms security Title: Stock Option conversion Or Exercise Price: 0.91 transaction Date: 2026-10-09 deemed Execution Date: transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 transaction Timeliness: transaction Shares: 75000 id: F1 transaction Price Per Share: 0 transaction Acquired Disposed Code: A exercise Date: 2026-10-09 id: F1 expiration Date: 2036-10-08 underlying Security Title: Common Stock underlying Security Shares: 75000 shares Owned Following Transaction: 75000 direct Or Indirect Ownership: D

Owner: WILSON GLYNN
Date: 2026-10-09
Code: A
Action: Grant or award
Quantity: 75000
Price: 0
Following holdings: 75,000
Reporting delay: 4 days
Filed terms and references: Filed terms
security Title: Stock Option
conversion Or Exercise Price: 0.91
transaction Date: 2026-10-09
deemed Execution Date:
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 75000
id: F1
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
exercise Date: 2026-10-09
id: F1
expiration Date: 2036-10-08
underlying Security Title: Common Stock
underlying Security Shares: 75000
shares Owned Following Transaction: 75000
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
WILSON GLYNN: Director.
F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.

Prepared automatically from public filing data. Report a correction.